PGV-1 is a Potent Antimitotic Agent

Abstract

Carcinogenesis may resulted from the malfunctioning of programmed cell death. Most of the anticancer drugs in
current use induce apoptosis in susceptible cells. The fact that disparate agent interacting with different targets seem
to induce cell death through some common mechanisms suggest that anticancer activity is determined by the ability
of inhibiting cell growth. Pentagamavunon-1 (PGV-1) is one of the curcumin analogues which showed to have
potency in inhibiting proliferation of T47D human breast carcinoma cells. The effects on T47D cells growth is
associated with cell cycle arrest in G2/M phase at the concentration of 2.5 ?M, followed by hyperploidy. The data on
polymerization assay, indicated that PGV-1 interact with tubulin in different manner from taxol. PGV-1 inhibit
tubulin polymerization on cell culture while taxol stabilized tubulin polymerization. Immunostainning data on
PGV-1 treated cells showed slightly tubulin condensation, while taxol treated cells showed tubulin condensation
distinctly at 12 minutes after releasing from depolymerizing agent.
In conclusion, PGV-1 represent a new microtubule inhibitor and has the potential to be developed for antimitotic
drug
Key words: Pentagamavunon-1, T47D, tubulin